Companion Diagnostics: Page 5

Invitae launches 2 IVD cancer tests in Europe

By LabPulse.com staff writers

Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.

February 15, 2022

AMP names new editor in chief for its journal

By LabPulse.com staff writers

Przygodzki will be replacing Barbara Zehnbauer, PhD, who has been the journal's EIC since January 2015. APM said that Zehnbauer "served with distinction" during her tenure as EIC. In 2020, the journal had an impact factor of 5.568 and its most recent CiteScore in 2020 is 8.0.

February 13, 2022

AACC to relaunch clinical lab show in Middle East

AACC said it is working closely with Abu Dhabi-based company Life Diagnostics to develop education and scientific programs paired with dynamic exhibits. The event's scientific program will feature experts from the U.S. and the Middle East who will share actionable information about the latest in clinical testing, according to the organizers.

February 9, 2022

Smartphone-based LAMP assay can detect COVID, flu

By Leah Sherwood

Smart LAMP is portable and inexpensive to set up (less than $100, according to the authors) and consists of a hot plate, cardboard box, and LED lights. The researchers designed the diagnostic to meet five criteria for rapid and frequent testing at the point of care: speed, sensitivity, low cost, scalability, and accessibility. The assay simultaneously analyzes up to 96 saliva samples per phone at a cost of less than $7 per test, the researchers noted.

January 27, 2022

Pillar's NGS lab receives certification, state permit

By LabPulse.com staff writers

The Natick, MA-based lab also received the state permit. All of this means the lab can support preclinical studies and clinical trials, with the longer-term potential to provide companion diagnostics for the company's pharmaceutical partners.

January 9, 2022

NIH announces accelerator diagnostics challenge

By LabPulse.com staff writers

The contest aims to spur and reward the development of prototypes for low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies, the agency said in a release.

December 6, 2021

Thermo Fisher releases new IVD system

By LabPulse.com staff writers

The system allows users to broaden their assay options with interchangeable 96-well and 384-well blocks and features set run, analysis, and report settings to decrease operator errors. It also includes remote desktop and touchscreen controls, facial authentication, and voice command, the company said.

November 9, 2021

PathAI partners with Roche for AI tech

By LabPulse.com staff writers

The companies said the partnership allows for broad access to digital pathology diagnostics to support clinical research and companion diagnostic programs globally.

October 14, 2021

Thermo Fisher gets FDA approval for lung cancer test

By LabPulse.com staff writers

The test will be used as a companion diagnostic to identify patients who are candidates for treatment with Exkivity (mobocertinib) from Takeda Pharmaceutical. The Oncomine Dx Target Test is intended to help identify patients who have epidermal growth factor receptor (EGFR) Exon20 insertion mutations.

September 16, 2021

Thermo Fisher, AstraZeneca to develop NGS companion diagnostics

By LabPulse.com staff writers

Their multiyear, global deal will help support AstraZeneca's therapy portfolio. Over 90% of AstraZeneca's clinical pipeline is targeted precision medicine therapies covering a range of therapeutic areas.

August 31, 2021

Agilent secures expanded CE Mark for cancer assay

By LabPulse.com staff writers

The test may now be used to identify esophageal cancer patients eligible for treatment with Keytruda, a monoclonal antibody developed by Merck that boosts the body's ability to fight cancer cells.

August 22, 2021

Tempus seeks FDA premarket approval for xT-Onco assay

By LabPulse.com staff writers

In addition to premarket approval, the submission includes companion diagnostic claims, tumor profiling claims, and microsatellite instability status, using DNA isolated from formalin-fixed paraffin embedded tumor tissue specimens and matched normal specimens.

August 17, 2021

Previous Page

Page 5 of 12

Next Page